Plain-English translation of NCT06716606 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who already completed one of two earlier trials testing for lung disease caused by connective tissue disorders like systemic sclerosis. Researchers want to see how safe and effective this medication is when patients continue taking it over the long term, and whether it continues to slow the decline in lung function and improve quality of life.
Interstitial lung disease—scarring of the lungs caused by connective tissue disorders—can get worse over time and limit how well people breathe. This trial tests whether long-term treatment with this medication can safely slow that decline and help patients live better.
You likely qualify if…
You likely don't qualify if…
You will continue to receive injections under your skin on a regular schedule. This is an open-label study, meaning both you and your doctors know you are receiving the medication. You will have regular visits to check how well the treatment is working, monitor your lung function, and watch for any side effects. The study will track whether the medication continues to slow lung disease progression and improve how you feel over time.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States
Argentina